Recursion, Novavax, Crispr Therapeutics Stocks Slip Premarket After Cancer Therapy Rally - Recursion Phar
Recursion Pharmaceuticals, Novavax, and CRISPR Therapeutics stocks experienced pre-market declines after a recent rally driven by positive Phase 3 results for an individualized mRNA cancer therapy from Merck & Co. and Moderna. Recursion also faced company-specific pressure from a director's plan to sell Class A shares. Despite these pre-market slips, all three stocks had closed significantly higher the previous day.
Novavax Stock Moves Higher Wednesday: What's Driving the Action?
Shares of Novavax Inc (NVAX) are trading higher due to a major clinical breakthrough in oncology by Merck & Co Inc and Moderna Inc. This success, specifically in an individualized mRNA cancer vaccine combined with Keytruda for advanced melanoma, has generated widespread positive momentum across the biotechnology sector. Novavax's proprietary Matrix-M adjuvant platform is also seen as a valuable asset, further supporting its rally.
Novavax Stock Moves Higher Wednesday: What's Driving the Action?
Novavax (NVAX) shares rose on Wednesday following a clinical breakthrough in the oncology space reported by Merck and Moderna. Their individualized mRNA cancer vaccine, combined with Keytruda, significantly improved recurrence-free survival in advanced melanoma patients, triggering a broad rally in the biopharmaceutical sector. Novavax's stock benefited from this industry-wide momentum and its own adjuvant platform, despite being known for infectious disease vaccines.
Novavax Inc. stock underperforms Tuesday when compared to competitors
Novavax Inc. (NVAX) stock fell 1.73% on Tuesday, closing at $7.93, while the broader market also experienced declines. The company's shares are currently trading 33.75% below their 52-week high of $11.97, which was reached on February 26th. This performance indicates an underperformance compared to its market competitors during the trading session.
Novavax, Inc. (NASDAQ:NVAX) Given Consensus Rating of "Hold" by Analysts
Analysts have issued a "Hold" consensus rating for Novavax (NASDAQ:NVAX), with an average 12-month price target of $13.00, significantly higher than its recent trading price of $8.05. Despite beating quarterly earnings estimates, the biopharmaceutical company reported a 76.2% year-over-year revenue decline and remains unprofitable. Institutional investors maintain significant ownership, with some firms increasing their stakes.
(NVAX) Volatility Zones as Tactical Triggers
This article analyzes Novavax Inc. (NVAX) using AI models, highlighting strong sentiment across all horizons and an exceptional 69.0:1 risk-reward setup. It outlines three distinct trading strategies—Position, Momentum Breakout, and Risk Hedging—tailored for different risk profiles, along with multi-timeframe signal analysis to provide tactical triggers for investors.
Novavax Inc. stock underperforms Friday when compared to competitors
Novavax Inc. (NVAX) shares dropped 1.11% on Friday, closing at $8.05, despite a three-day winning streak being snapped. This underperformance occurred on a negative trading day for the broader market, with both the NASDAQ Composite and Dow Jones Industrial Average also experiencing declines.
How Novavax’s (NVAX) Earnings Slide and New Share Shelf Will Impact Investors
Novavax (NVAX) recently reported a significant decline in its second-quarter revenue and swung to a net loss, moving from profitability to a loss of US$53.39 million. The company also filed a US$82.47 million shelf registration for common shares tied to an ESOP offering. These developments raise concerns about Novavax's funding and earnings profile, potentially impacting investor perceptions and the stock's future performance.
Novavax Inc. stock outperforms competitors on strong trading day
Novavax Inc. (NVAX) shares rose 2.26% to $8.14, outperforming major indices like the NASDAQ Composite and Dow Jones Industrial Average. This marked the third consecutive day of gains for the stock. The positive performance occurred during a favorable trading session for the broader market.
How Novavax’s (NVAX) Earnings Slide and New Share Shelf Will Impact Investors
Novavax (NVAX) reported a significant second-quarter revenue drop to US$56.7 million from US$239.24 million, resulting in a net loss of US$53.39 million, and filed an US$82.47 million shelf registration for new shares. This shift from profitability to loss, alongside potential share dilution, raises concerns about the company's funding and future earnings. Investors are now closely watching how these developments affect Novavax's ability to execute partner-driven milestones and manage its balance sheet.
Bank of America Corp DE Cuts Stock Holdings in Novavax, Inc. $NVAX
Bank of America Corp DE reduced its stock holdings in Novavax, Inc. (NASDAQ:NVAX) by 19.9% in the first quarter, selling over 1.65 million shares and retaining 6.64 million shares valued at approximately $54 million. Institutional investors collectively own 53.04% of the company. Analyst sentiment for Novavax is mixed, with a consensus "Hold" rating and an average price target of $13, while the company recently reported a quarterly loss despite exceeding revenue estimates.
Novavax, Inc. (NVAX) Stock Analysis: Growth Potential Amidst A 77% Upside
Novavax, Inc. (NVAX), a biotechnology company specializing in vaccines, shows a promising potential upside of 77.47% according to analyst ratings, despite current financial challenges including a 76.30% revenue decline. The company's strategic partnerships and product pipeline, including Nuvaxovid and the R21 Matrix-M malaria vaccine, position it for potential growth, though it represents a high-risk, high-reward investment due to its volatile nature and lack of immediate shareholder returns. Investors should weigh its innovative product development against its complex financial metrics and the speculative nature inherent in the biotech sector.
Renaissance Technologies LLC Invests $4.05 Million in Novavax, Inc. $NVAX
Renaissance Technologies LLC has acquired a new position in Novavax, Inc. (NASDAQ:NVAX), purchasing 497,383 shares valued at approximately $4.05 million. This investment represents a 0.30% stake in Novavax, which recently reported better-than-expected Q2 earnings, though revenue fell significantly year-over-year. The biopharmaceutical company has a consensus "Hold" rating from analysts, with a mixed sentiment reflected in recent upgrades and downgrades, and has raised its 2026 revenue outlook.
Novavax Inc. stock outperforms competitors on strong trading day
Novavax Inc. (NVAX) stock rallied 2.71% to $7.95 on Friday, outperforming its competitors and the broader market. This marked the stock's fifth consecutive day of gains, contributing to a strong trading session where the NASDAQ Composite Index rose 1.30% and the Dow Jones Industrial Average rose 0.28%.
State Street Corporation (NYSE: STT) discloses 7.1% ownership of Novavax
State Street Corporation has disclosed a 7.1% ownership stake in Novavax, Inc., through its investment management affiliates. This beneficial ownership amounts to 11,740,566 shares of common stock. State Street holds shared voting power over 11,281,036 shares and shared dispositive power over all beneficially owned shares, with no sole voting or dispositive power.
Novavax, Inc. Stock 12‑Month Price Target Cut to $13.75, Implies 78% Upside
Novavax, Inc.'s average 12-month price target has been reduced to $13.75 from $13.88, according to 8 analysts, with forecasts ranging from $7 to $25 per share. This new target implies a potential 78% upside based on the Aug. 6 closing price. The consensus analyst rating for Novavax has shifted to "Hold," with 4 Buy, 1 Hold, and 3 Sell recommendations.
Novavax Inc (NVAX) (Q2 2026) Earnings Call Highlights: Matrix-M Momentum Drives Revenue ...
Novavax Inc. (NVAX) reported its Q2 2026 earnings, highlighting significant progress with its Matrix-M adjuvant technology through partnerships with top pharmaceutical companies, including Sanofi. The company increased its full-year 2026 revenue guidance to $235 million-$275 million, driven by strong demand for Matrix-M, and aims for non-GAAP profitability by 2028. Despite a net loss of $53 million for the quarter, largely due to the absence of one-time milestone payments, Novavax anticipates extending its cash runway into 2029.
Novavax (NVAX) Reports Q2 Loss, Tops Revenue Estimates
Novavax (NVAX) reported a Q2 loss of $0.32 per share, outperforming the Zacks Consensus Estimate of a $0.36 loss, and topped revenue estimates with $56.7 million. This marks the fourth consecutive quarter the company has surpassed both EPS and revenue expectations. Despite a year-over-year decrease in revenues, Novavax shares have gained 14.6% year-to-date, and the company currently holds a Zacks Rank #1 (Strong Buy).
Novavax raises annual revenue forecast as licensing bets offset weak vaccine demand
Novavax has increased its annual revenue forecast, driven by licensing and supply agreements for its vaccine platform rather than direct vaccine sales. The company is strategically shifting its focus to these partnerships, particularly with Sanofi, to achieve profitability by 2028, even as its second-quarter revenue saw a significant year-on-year decline. CEO John Jacobs also noted positive momentum in the U.S. regulatory environment for seasonal respiratory vaccines, following recent approvals for combination shots from competitors.
Novavax Raises 2026 Revenue Outlook After Q2 Earnings Beat
Novavax (NASDAQ: NVAX) exceeded Wall Street's Q2 earnings expectations, leading to a bump in its 2026 revenue guidance. The biotechnology company reported $57 million in revenue, driven by increased product sales despite a significant year-over-year decline due to the absence of large partner payments received in the prior year. Novavax's CEO highlighted upcoming partner milestones and progress in R&D programs.
Novavax raises 2026 outlook after Q2 beat (NVAX:NASDAQ)
Novavax (NVAX) shares rose after the company reported better-than-expected Q2 2026 financials, beating revenue estimates by $3.7 million with $57 million in revenue. Following this performance, the COVID-19 vaccine maker also raised its full-year revenue guidance.
Earnings Flash (NVAX) Novavax, Inc. Reports Q2 Revenue $56.7M, Vs. FactSet Est of $52.5M
Novavax, Inc. (NVAX) announced its Q2 revenue of $56.7 million, surpassing the FactSet estimate of $52.5 million. This earnings flash indicates the company's financial performance for the quarter, highlighting better-than-expected revenue generation.
NOVAVAX INC 2Q 2026: Revenue $56.7M, EPS ($0.32) — 10-Q Summary
NOVAVAX INC reported a significant decline in its second-quarter 2026 financial results, with revenue falling to $56.7 million and a net loss of $53.39 million, primarily due to fewer one-time milestone and agreement-related items compared to the prior year. The company's business strategy has shifted with the transfer of commercial lead for Nuvaxovid to Sanofi, impacting direct vaccine sales, while focusing on partnerships and pipeline advancements. Operational changes include ongoing restructuring, cost containment, and technology transfer milestones.
Novavax Reports Second Quarter 2026 Financial Results and Operational Highlights
Novavax announced its Q2 2026 financial results, reporting $57 million in total revenue and raising its full-year 2026 revenue framework to between $235 million and $275 million. The company also improved its GAAP Combined R&D and SG&A expense guidance. Key operational highlights include continued progress with the Sanofi partnership, advanced discussions with regulators for the Phase 3 COVID-19-Influenza Combination trial, and ongoing development of its C. difficile vaccine candidate.
Novavax (Nasdaq: NVAX) Q2 revenue $57M, swings to $53M loss
Novavax reported a significant financial downturn in Q2 2026, swinging to a $53 million net loss from a $107 million net income in Q2 2025, with total revenue decreasing by 76% to $57 million. This drop is primarily attributed to the absence of large milestone payments received in the prior year. Despite the revenue decline, the company raised its full-year 2026 adjusted total revenue guidance and reduced its GAAP combined R&D and SG&A expense guidance, reflecting ongoing cost-reduction efforts and its strategic partnership with Sanofi.
Novavax earnings up next: Can partnerships offset vaccine slump?
Novavax is set to report its second-quarter earnings, with investors focused on whether its new partnership strategy can compensate for declining COVID-19 vaccine sales. Analysts anticipate a significant revenue decrease and a loss per share, despite a "buy" rating from Wall Street analysts. The company is transitioning from a vaccine manufacturer to a technology licensing company, and updates on its collaborations and financial stability will be key.
Price-Driven Insight from (NVAX) for Rule-Based Strategy
This article provides a price-driven analysis for Novavax Inc. (NVAX) using AI models, outlining distinct trading strategies for various risk profiles. It highlights a positive near-term sentiment with potential mid-term weak bias within long-term strength, and identifies key support and resistance levels. The analysis also presents an exceptional risk-reward setup targeting an 18.0% gain against a 0.3% risk.
NOVAVAX INC 2Q 2026: Revenue $56.7M, EPS ($0.32) — 10-Q Summary
NOVAVAX INC (NVAX) reported a significant year-over-year decline in its second-quarter 2026 revenue and a return to a net loss, primarily due to fewer one-time milestone and agreement-related items compared to the previous year. The company's revenue dropped by 76.3% to $56.7M, with a diluted EPS of ($0.32). Despite financial setbacks, Novavax highlighted business developments including a channel shift for Nuvaxovid to Sanofi, expanded Matrix-M® collaborations, product pipeline advancements, and ongoing cost containment efforts.
Novavax Inc expected to post a loss of 39 cents a share - Earnings Preview
Novavax Inc is projected to report a loss of 39 cents per share. This earnings preview is based on information from Refinitiv. The full article can be accessed on TradingView for unlimited access to news from Reuters and other sources.
Novavax Inc. stock outperforms competitors on strong trading day
Novavax Inc. (NVAX) shares rose 3.37% to $7.66 on Tuesday, outperforming competitors on a strong trading day for the stock market. This marks the second consecutive day of gains for Novavax, as both the NASDAQ Composite Index and the Dow Jones Industrial Average also saw significant increases.
Novavax Inc expected to post a loss of 39 cents a share - Earnings Preview
Novavax Inc is projected to report a loss of 39 cents per share, according to this earnings preview. The full article is available through TradingView News, which aggregates content from various sources including Reuters. This financial forecast provides a key insight into the company's expected performance.
NVAX Stock Rises Ahead Of Q2 Earnings As Focus Shifts To Licensing Deals
Novavax (NVAX) stock rose ahead of its Q2 earnings release, as the company continues to pivot its strategy from large-scale COVID-19 vaccine sales to licensing its proprietary Matrix-M adjuvant. Investors are anticipating updates on cash position and progress with Matrix-M deals, especially after a key licensing deal with Pfizer. Retail investors on Stocktwits remain bullish on NVAX, even speculating on new opportunities from potential outbreaks.
Novavax Inc. stock rises Monday, still underperforms market
Novavax Inc. (NVAX) stock increased by 1.23% on Monday, closing at $7.41, despite a generally favorable trading session for the market where the NASDAQ Composite and Dow Jones Industrial Average also rose. The company's stock, however, remains 38.10% below its 52-week high of $11.97, which it reached on February 26th.
Novavax Inc. stock underperforms Friday when compared to competitors
Novavax Inc. (NVAX) shares dropped 1.61% on Friday, closing at $7.32, despite an overall positive trading day for the broader market. The stock finished 38.85% below its 52-week high, while the NASDAQ Composite and Dow Jones Industrial Average both saw gains.
Novavax sets Aug. 6 webcast to discuss second-quarter results
Novavax (Nasdaq: NVAX) announced it will release its second-quarter 2026 financial results on Thursday, August 6, 2026, before the U.S. market opens. Following the release, the company will host a webcast and conference call at 8:30 a.m. ET to discuss financial results and operational highlights. Investors can access the live webcast at ir.novavax.com/events or join by phone, with replay options available afterward.
Novavax to Report Second Quarter 2026 Financial Results on August 6, 2026
Novavax, Inc. announced it will release its second quarter 2026 financial results on Thursday, August 6, 2026, before the U.S. financial markets open. Following the release, company management will host a webcast and conference call at 8:30 a.m. ET to discuss the financial results and operational highlights. Details for joining the conference call and accessing the webcast replay are provided.
Novavax Inc. stock rises Thursday, still underperforms market
Novavax Inc. (NVAX) stock increased by 1.36% on Thursday, closing at $7.44. Despite this rise, the stock underperformed the broader market, as the NASDAQ Composite Index and the Dow Jones Industrial Average saw larger gains. This increase broke a two-day losing streak for Novavax.
Novavax to Report Second Quarter 2026 Financial Results on August 6, 2026
Novavax, Inc. announced it will release its second quarter 2026 financial results on Thursday, August 6, 2026, before the U.S. financial markets open. Following the release, company management will host a webcast and conference call at 8:30 a.m. ET to discuss the financial results and operational highlights. Details for registering and joining the call, as well as accessing the webcast, have been provided.
Novavax to report Q2 2026 earnings on August 6 with webcast and call at 8:30 a.m. ET
Novavax (NVAX) announced it will release its second-quarter 2026 financial results on August 6 before the U.S. market opens, followed by a webcast and conference call at 8:30 a.m. Eastern Time. The company will discuss its results and operational highlights for investors and interested parties. This announcement comes as Novavax, currently valued at an enterprise value of approximately $716 million, continues its vaccine development efforts, notably with its Matrix-M adjuvant.
Novavax to Report Second Quarter 2026 Financial Results on August 6, 2026
Novavax, Inc. announced it will release its second quarter 2026 financial results on Thursday, August 6, 2026, before the U.S. financial markets open. The company will also host a webcast and conference call at 8:30 a.m. Eastern Time to discuss the results and operational highlights. Details for registration, dial-in, and webcast access have been provided for participants, along with replay information.
Novavax to Report Second Quarter 2026 Financial Results on August 6, 2026
Novavax, Inc. announced it will release its second quarter 2026 financial results before U.S. financial markets open on Thursday, August 6, 2026. Following the release, company management will host a webcast and conference call at 8:30 a.m. ET to discuss the financial results and operational highlights. Details for registering for the call and accessing the live webcast and replay are provided.
Novavax to Report Second Quarter 2026 Financial Results on August 6, 2026
Novavax, Inc. announced its plan to release second-quarter 2026 financial results before the U.S. financial markets open on Thursday, August 6, 2026. Following the release, company management will host a webcast and conference call at 8:30 a.m. ET to discuss the financial results and operational highlights. Details for registering for the phone conference or accessing the live webcast are provided, with a replay available afterward.
Novavax (NVAX) Stock Falls Amid Market Uptick: What Investors Need to Know
Novavax (NVAX) shares fell 1.6% in the latest trading session, contrasting with the broader market's uptick. The stock has experienced a significant decline over the past month, underperforming its sector and the S&P 500. Investors are now looking forward to the company's upcoming earnings report, with estimates projecting a substantial year-over-year decline in both EPS and revenue, although the stock currently holds a Zacks Rank of #1 (Strong Buy).
Novavax (NVAX) Stock Falls Amid Market Uptick: What Investors Need to Know
Novavax (NVAX) stock fell by 1.6% in recent trading, despite a general market uptick, and has seen a nearly 20% decline over the past month. The company is projected to report significant year-over-year declines in EPS and revenue for its upcoming earnings release. Despite these financial projections, Novavax currently holds a Zacks Rank of #1 (Strong Buy) due to favorable analyst estimate revisions, suggesting potential for outperformance.
Novavax Inc (NVAX) Shareholder Structure: Major Shareholders & Institutional Holdings
This article details the shareholder structure of Novavax Inc (NVAX), identifying its major institutional holders. Key information includes the top shareholders like Shah Capital Management, BlackRock, and State Street, and a breakdown of shareholder types. It also provides a historical overview of institutional shareholdings and recent changes in positions by significant investors.
Novavax Inc (NVAX) Cash Flow
This article provides a detailed cash flow statement for Novavax Inc (NVAX), including operating, investing, and financing cash flows presented quarterly and annually. It outlines key financial metrics and defines terms like operating cash flow, investing cash flow, financing cash flow, and free cash flow to help evaluate the company's financial health. The data shows various fluctuations in cash flow activities over multiple fiscal years, highlighting different aspects of the company's financial performance.
Novavax Inc (NVAX) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution
The article provides a detailed revenue breakdown for Novavax Inc (NVAX) for FY2025, categorized by business segments and regional contributions. It shows that product sales account for 60.97% of revenue, with licensing and royalties making up 39.03%. Regionally, Canada is the largest revenue contributor at 51.24%, followed by the United States at 36.10%.
NVAX|Novavax Inc|Price:7.460|Chg%:-0.365
Novavax Inc. (NVAX) shows relatively stable fundamentals and high growth potential, with its valuation considered fairly valued within the Biotechnology & Medical Research industry. The stock price is expected to remain stable in the medium term, trading sideways between support and resistance levels. Institutional ownership is high, and analysts have largely rated it as "Hold," with a target price indicating significant upside space.
Novavax Inc (NVAX) Technical Analysis: Support, Resistance, Indicators & Moving Averages
This article provides a technical analysis of Novavax Inc (NVAX), detailing its current price momentum, support and resistance levels, and signals from various technical indicators and moving averages. As of July 24, 2026, NVAX had a price momentum score of 4.46 and was trading between a resistance level of $9.23 and a support level of $6.57. The analysis indicates "Sell" signals across most technical indicators and moving averages, with an overall "Neutral" signal based on technical analysis.
Novavax, Inc. Revenue Breakdown – NASDAQ:NVAX
This article provides a revenue breakdown for Novavax, Inc. (NASDAQ: NVAX) for the last year. The company generated $1.10 billion USD in total revenue, with its Innovative Vaccines segment contributing the most at $1.12 billion USD. The largest regional contribution came from Rest of North America, accounting for $575.67 million USD.
